Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials
(RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness …

Background Clinical trials have demonstrated galcanezumab as safe and effective in
migraine prevention. However, real-life data are still lacking and overlook the impact of …

Abstract Background and Purpose To evaluate the 1‐year effectiveness and tolerability of
galcanezumab in real life and the prognostic indicators of persistent response. Methods …

Background Many patients who require migraine preventive treatment have not been able to
tolerate or have not responded to multiple previous preventive medications. We aimed to …

Background Maintenance of effect following treatment with galcanezumab compared to
placebo in adult patients with episodic or chronic migraine was evaluated. Methods In 2 …

Background Patients with high-frequency episodic migraine (HFEM) have a greater disease
burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse …

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-
related peptide, used for migraine prevention. Methods A global, double-blind, 6-month …

Background and purpose A rapid response to preventive therapy is of pivotal importance in
severely disabled patients with chronic migraine (CM) and diverse preventive treatment …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the
calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical …

Objective: This study was designed to assess the efficacy and safety of galcanezumab in
comparison with placebo for the prevention of migraine in Japanese patients with episodic …